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First, Dr Kong and Dr Morel claimed that ballooning for ischemic postconditioning should be performed proximal to the culprit lesion rather than within the stent to reduce microembolism. However, there is no direct evidence on association between the location of ballooning for ischemic postconditioning and microembolism or infarct size during primary percutaneous coronary intervention (PCI). Moreover, as we described, the balloon was inflated with low-pressure (<6 atm) inflations to avoid distal embolization. 1 On the contrary, to perform iterative balloon angioplasty proximal to the culprit lesion results in geographic mismatch and may increase the risk of target vessel revascularization and myocardial infarction. 2 This possible disadvantage of proximal ballooning could not be evaluated in previous small studies. Second, Dr Morel was concerned with the very low rate of direct stenting in our study. However, direct stenting has been reported to be used in fewer than one-third of patients undergoing primary PCI. 3, 4 Direct stenting is not feasible in some patients with TIMI grade 0 flow because the distal segment beyond the culprit lesion cannot be evaluated. Moreover, no significant benefit of postconditioning was observed in patients undergoing direct stenting in subgroup analysis of the POST trial. He also claimed that the rate of complete ST resolution was very low (41%) in our study. However, the rate of complete ST resolution was reported as 40% to 50% in recent major trials. 5, 6 Third, Dr Kong stated that baseline cardiovascular medication may be related to the failure to demonstrate the cardioprotection of postconditioning in PCI and β-blockers may interfere with or even abrogate the infarct size-limiting effect by preconditioning or postconditioning in animal study. We admit that the lack of information on baseline medication may be 1 of the limitations of our study. However, if the benefit of ischemic postconditioning is abrogated by β-blockers, do we have to avoid the use of β-blockers in patients undergoing primary PCI to hold the infarct size-limiting effect by ischemic postconditioning?
Our POST trial was a multicenter, prospective, randomized, openlabel, blinded end point trial that was the largest study on the effect of ischemic postconditioning until now. The study population was similar to a majority of primary PCI trials regarding age and sex distribution and symptom onset to reperfusion time. 7 Baseline clinical, angiographic, and procedural data were well balanced between the postconditioning group and the control group. Cardioprotective effects of postconditioning were not found in any of the prespecified subgroups. Taken together, we believe that the negative results of the POST trial resulted from the lack of actual benefit from ischemic postconditioning rather than study design. It is unlikely that ischemic postconditioning is protective in patients undergoing primary PCI with current standard practice. We hope that other conditioning strategies such as remote ischemic preconditioning or pharmacological conditioning can reduce infarct size and improve long-term clinical outcomes.
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